目的观察经肝动脉插管栓塞和灌注化疗药物羟基喜树碱、５ＦＵ、丝裂霉素（ＭＭＣ）、顺铂治疗（ＴＡＣＥ）进展期肝癌（ＨＣＣ）２１例的疗效和副作用．方法应用ＴＡＣＥ治疗２１例中晚期ＨＣＣ患者，其中Ⅱ期１５例，Ⅲ期６例．结果接受ＴＡＣＥ患者２１例，治疗总有效率为８０９％，平均生存期９１ｍｏ，半年和一年生存率分别为７１５％和４２４％．Ⅱ期患者获得的平均生存期、半年和一年生存率分别为１０５ｍｏ，８６７％，６０％；明显优于Ⅲ期患者的５３ｍｏ，３６７％，０％（Ｐ＜００１）．多次治疗的平均生存期为１１２ｍｏ，明显优于单次治疗的６８ｍｏ（Ｐ＜００１）．副作用有恶心、呕吐、发热、白细胞下降和肝功能异常．结论羟基喜树碱经肝动脉灌注联合栓塞是治疗进展期ＨＣＣ的有效手段． Objective To observe the efficacy and side effects of transcatheter arterial intubation embolization and infusion of chemotherapy drugs hydroxycamptothecine, 5FU, mitomycin (MMC), cisplatin treatment (TACE) advanced hepatocellular carcinoma (HCC) in 21 cases. Methods TACE was used to treat 21 cases of advanced HCC, including 15 cases of stage II and 6 cases of stage III. Results TACE was performed in 21 patients. The total effective rate was 80.9%. The average survival time was 9 days and 1 month. The half-year and one-year survival rates were 71.5% and 42.4%, respectively. The average survival, half-year and one-year survival rates of stage II patients were 105mo, 867%, 60% respectively; they were significantly better than those of stage III patients (53mo, 367%, 0%). 001). The average survival time of multiple treatments was 112mo, which was significantly better than that of single treatment 68mo (P<001). Side effects are nausea, vomiting, fever, leukopenia and abnormal liver function. 2. Conclusion Hepatic arterial infusion combined with HCPT is an effective method to treat advanced HCC.